

Cortellis Product Intelligence


医薬品関連の契約情報を収集する

ディール情報コンテンツは契約締結、買収候補先やパートナー提携先の探索、競合企業の調査等に必要な情報を提供します。

注: 本コンテンツをご利用頂けるのはCortellis Product IntelligenceのGlobalとPremiumライセンスをご契約のユーザーのみとなります。

検索事例: ペムブロリズマブに関する契約情報の収集

1. クイックサーチからペムブロリズマブの製品レコードを検索



2. 製品レコードのディールタブをクリックすると、ディールごとに関連する企業やディールの効力を発揮する国/地域、ディールのステータスやバリュー（情報が付与されたディールに限る）といった情報を明確に確認できます。

pembrolizumab							
PRODUCT KEY INSIGHTS API MANUFACTURERS REGULATORY FILINGS APPROVALS CONSTRAINT DATE FORECAST & EXCLUSIVITIES PATENTS & SPCS US PATENT CHALLENGES GLOBAL LITIGATION DEALS COMPETITIVE INSIGHTS R&D							
SCIENTIFIC LAUNCHES & PACK PRICES US MARKET SHARE LATAM MARKET SHARE							
Deals							
Filters: Partner Country/Territory Agreement Type							
<div> Customize Columns Export </div>							
DEAL TITLE	PRINCIPAL COMPANY	PRINCIPAL COUNTRY/ TERRITORY	PRINCIPAL CORPORATE GROUP	PARTNER COMPANY	PARTNER COUNTRY/ TERRITORY	PARTNER CORPORATE GROUP	AGREE
BiInvent to evaluate BI-1607 in combination with ipilimumab and MSD's Keytruda against metastatic melanoma	BiInvent International AB	Sweden	BiInvent International AB	MSD International Business G...	Switzerland	Merck and Co Inc	Drug -
CytomX to evaluate CX-801 in combination with Merck's pembrolizumab against cancer	CytomX Therapeutics Inc	US	CytomX Therapeutics LLC	Merck & Co Inc	US	Merck and Co Inc	Drug -
University of California to							

表示する項目列のカスタマイズやデータ出力が可能です。

3. デールタイトルをクリックするとデール情報の詳細を確認できます。

Deals	
<div> <div>Filters</div> <div>Partner Country/Territory</div> </div>	
<div> <div>Customize Columns</div> <div>Export</div> </div>	
DEAL TITLE	PRINCIPAL CO
BiInvent to evaluate BI-1607 in combination with ipilimumab and MSD's Keytruda against metastatic melanoma	BiInvent Inter
CytomX to evaluate CX-801 in combination with Merck's pembrolizumab against cancer	CytomX Therap
University of California to conduct phase II study of ALX Oncology's evorpacept in combination with pembrolizumab against oropharyngeal cancer	University of Ci
University of Chicago Medicine to conduct a phase II/III for HOOKIPA Pharma's HB-200 in combination with	The University

Deal Details

Details and Information

Deal Title

BiInvent to evaluate BI-1607 in combination with ipilimumab and MSD's Keytruda against metastatic melanoma

More Information

[Cortellis Competitive Intelligence](#)

Status

Active

Principal Company

[BiInvent International AB](#)

Principal Country/Territory

Sweden

Partner Company

[MSD International Business GmbH](#)

Partner Country/Territory

Switzerland

Deal Start Date

17-Jul-2024

Deal End Date

No data

Agreement Type

Drug - Early Research/Development

Value (\$M)

No data

Involved Products

[ipilimumab](#)

[pembrolizumab](#)

Events

- 17-Jul-2024** - In July 2024, BiInvent International signed a clinical trial collaboration and supply agreement to evaluate BI-1607 in combination with Ipilimumab and MSD International Business' Keytruda (pembrolizumab) against metastatic melanoma. - BI-1607 is a phase II human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targeting Fc gamma receptor IIB for advanced solid tumors including breast, gastric, gastroesophageal junction adenocarcinoma and esophageal cancer. - Keytruda is a launched humanized IgG4 monoclonal antibody against programmed cell death protein-1 (PD-1) for different types of cancer. - Ipilimumab is a launched immunostimulatory human mAb against cytotoxic T-lymphocyte antigen-4 (CTLA-4) for cancers. - MSD would provide Keytruda for phase II open-label study. - Financial terms were not disclosed.

Sources

BiInvent International AB, "BiInvent Announces New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1607 in Combination with KEYTRUDA (Pembrolizumab) and Ipilimumab", Press Release, issue: July 17, 2024

【製品に関するお問い合わせ】 クラリベイト カスタマーケア (ts.support.jp@clarivate.com)